Compare Stocks: ALZN, BCTX, ATYR, and ALGS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.55 -0.2%	$5.76	$3.98 ▼ $13.69	$35.47M	2.34	51,759 shs	59,568 shs
ALZN Alzamend Neuro	$1.82 -6.2%	$1.56	$0.84 ▼ $2.68	$9.36M	0.23	113,953 shs	150,513 shs
ATYR aTyr Pharma	$0.34 -10.0%	$0.48	$0.32 ▼ $1.12	$34.96M	0.53	824,371 shs	129.62 million shs
BCTX Briacell Therap	$4.28 +6.7%	$3.66	$2.60 ▼ $14.68	$35.58M	1.1	165,114 shs	241,713 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	-0.18%	+7.35%	-25.70%	-0.36%	-48.37%
ALZN Alzamend Neuro	-6.19%	-1.09%	+13.75%	+51.67%	-23.53%
ATYR aTyr Pharma	-10.02%	-10.33%	-40.77%	-36.00%	-64.50%
BCTX Briacell Therap	+6.73%	+1.42%	+13.53%	+39.87%	-58.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.55 -0.2%	$5.76	$3.98 ▼ $13.69	$35.47M	2.34	51,759 shs	59,568 shs
ALZN Alzamend Neuro	$1.82 -6.2%	$1.56	$0.84 ▼ $2.68	$9.36M	0.23	113,953 shs	150,513 shs
ATYR aTyr Pharma	$0.34 -10.0%	$0.48	$0.32 ▼ $1.12	$34.96M	0.53	824,371 shs	129.62 million shs
BCTX Briacell Therap	$4.28 +6.7%	$3.66	$2.60 ▼ $14.68	$35.58M	1.1	165,114 shs	241,713 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	-0.18%	+7.35%	-25.70%	-0.36%	-48.37%
ALZN Alzamend Neuro	-6.19%	-1.09%	+13.75%	+51.67%	-23.53%
ATYR aTyr Pharma	-10.02%	-10.33%	-40.77%	-36.00%	-64.50%
BCTX Briacell Therap	+6.73%	+1.42%	+13.53%	+39.87%	-58.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	2.86	Moderate Buy	$38.50	593.69% Upside
ALZN Alzamend Neuro	2.00	Hold	$28.00	1,438.46% Upside
ATYR aTyr Pharma	2.67	Moderate Buy	N/A	N/A
BCTX Briacell Therap	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ALZN, BCTX, ATYR, and ALGS Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/16/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/17/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/13/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/31/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$2.19M	15.81	N/A	N/A	$8.67 per share	0.64
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$1.20 per share	N/A
ATYR aTyr Pharma	$190K	174.29	N/A	N/A	$0.69 per share	0.49
BCTX Briacell Therap	N/A	N/A	N/A	N/A	$9.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$24.19M	-$7.30	N/A	N/A	N/A	-241.01%	-160.72%	-92.30%	11/5/2026 (Estimated)
ALZN Alzamend Neuro	-$8.77M	-$2.30	N/A	N/A	N/A	N/A	-277.88%	-184.20%	12/8/2026 (Estimated)
ATYR aTyr Pharma	-$74.12M	-$0.62	N/A	N/A	N/A	N/A	-95.89%	-69.67%	11/5/2026 (Estimated)
BCTX Briacell Therap	-$26.31M	-$7.92	N/A	N/A	N/A	N/A	-153.53%	-129.26%	N/A

Latest ALZN, BCTX, ATYR, and ALGS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2026	Q1 2027	ALZN Alzamend Neuro	-$0.56	-$0.68	-$0.12	-$0.68	N/A	N/A
8/7/2026	Q2 2026	ATYR aTyr Pharma	-$0.1214	-$0.11	+$0.0114	-$0.11	N/A	N/A
8/6/2026	Q2 2026	ALGS Aligos Therapeutics	-$1.09	-$0.14	+$0.95	-$0.14	$24.68 million	$27.78 million
7/22/2026	Q4 2026	ALZN Alzamend Neuro	-$0.67	-$0.74	-$0.07	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
BCTX Briacell Therap	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	2.19	2.19
ALZN Alzamend Neuro	N/A	3.01	3.01
ATYR aTyr Pharma	N/A	5.12	5.12
BCTX Briacell Therap	N/A	7.07	7.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
ALZN Alzamend Neuro	49.61%
ATYR aTyr Pharma	61.72%
BCTX Briacell Therap	15.42%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	7.80%
ALZN Alzamend Neuro	1.39%
ATYR aTyr Pharma	5.03%
BCTX Briacell Therap	0.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	82	6.24 million	5.76 million	No Data
ALZN Alzamend Neuro	6	4.83 million	4.76 million	No Data
ATYR aTyr Pharma	58	98.09 million	93.15 million	Optionable
BCTX Briacell Therap	4	8.70 million	8.64 million	No Data

ALZN, BCTX, ATYR, and ALGS Headlines

Recent News About These Companies

Briacell Therap (NASDAQ:BCTX) Short Interest Update

September 18, 2026 | americanbankingnews.com

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

September 14, 2026 | markets.businessinsider.com

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

September 14, 2026 | globenewswire.com

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

September 8, 2026 | globenewswire.com

BriaCell shares turn volatile after melanoma vaccine development milestone

August 24, 2026 | msn.com

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

August 24, 2026 | globenewswire.com

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

August 5, 2026 | globenewswire.com

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

July 16, 2026 | globenewswire.com

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

July 7, 2026 | globenewswire.com

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

June 25, 2026 | globenewswire.com

BriaCell Therapeutics Announces Closing of Offering

June 2, 2026 | globenewswire.com

BriaCell Presents Positive Clinical Data at ASCO 2026

June 1, 2026 | globenewswire.com

BriaCell Therapeutics Announces Pricing of Offering

May 31, 2026 | globenewswire.com

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

May 26, 2026 | globenewswire.com

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

May 22, 2026 | globenewswire.com

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

May 15, 2026 | globenewswire.com

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

May 14, 2026 | globenewswire.com

BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

May 13, 2026 | markets.businessinsider.com

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

May 13, 2026 | globenewswire.com

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

May 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN, BCTX, ATYR, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$5.55 -0.01 (-0.18%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$6.02 +0.47 (+8.45%)

As of 04:09 AM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Alzamend Neuro NASDAQ:ALZN

$1.82 -0.12 (-6.19%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$1.83 +0.01 (+0.33%)

As of 04:00 AM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

aTyr Pharma NASDAQ:ATYR

$0.34 -0.04 (-10.02%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$0.32 -0.01 (-4.03%)

As of 04:16 AM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Briacell Therap NASDAQ:BCTX

$4.28 +0.27 (+6.73%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$4.28 0.00 (0.00%)

As of 09/24/2026 07:30 PM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALZN, BCTX, ATYR, and ALGS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALZN, BCTX, ATYR, and ALGS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALZN, BCTX, ATYR, and ALGS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN, BCTX, ATYR, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Alzamend Neuro NASDAQ:ALZN

aTyr Pharma NASDAQ:ATYR

Briacell Therap NASDAQ:BCTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALZN, BCTX, ATYR, and ALGS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALZN, BCTX, ATYR, and ALGS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALZN, BCTX, ATYR, and ALGS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN, BCTX, ATYR, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Alzamend Neuro NASDAQ:ALZN

aTyr Pharma NASDAQ:ATYR

Briacell Therap NASDAQ:BCTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools